CD4+CD25− cells and CD4+CD25+ cells (hereinafter Tregs) were isolated from the PBMC population with the help of immunomagnetic beads as previously described14 (link). CD4+CD25− cells were further analyzed and purified using CD7 expression. In short, CD4+CD25− cells were treated with anti-CD7 (PE-conjugated) for 30 min followed by incubation with anti-PE antibody-conjugated microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) for 15 min (4 °C). Then, the resulting CD4+CD25−CD7+ cells and CD4+CD25−CD7− cells were purified by positive and negative selection, respectively, with MS separation columns (Miltenyi Biotec). CD4+CD25−CD7+ cells were further analyzed and sorted according to their levels of CD43 and CD45 expression (i.e., CD43low, CD43high, CD45low, and CD45high).
Similarly, CD4+CD25+ cells were treated with anti-Gal1 (PE-conjugated) for 30 min followed by incubation with anti-PE antibody-conjugated microbeads (Miltenyi Biotec) for 15 min (4 °C). Then, the resulting CD4+CD25+Gal1+ cells and CD4+CD25+Gal1− cells were purified by positive and negative selection, respectively, with MS separation columns (Miltenyi Biotec) and were further analyzed and sorted according to their levels of CD25 expression (i.e., CD25low, CD25med, and CD25high).
+ Open protocol